Valuation check: TECH's P/E ratio is 61.85, above the Healthcare sector average of 25.3.
Get informed when a big investor buys or sells
+ Follow61.85
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for TECH is 61.85. That is above the Healthcare sector average of 25.3. Investors often review this figure alongside Bio-Techne's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, TECH currently prints 61.85 for P/E ratio, while the sector average sits near 25.3. That is roughly 144.5% above the sector mean. Large gaps often invite a closer look at Bio-Techne's growth, margins, and balance sheet.
A P/E ratio of 61.85 for Bio-Techne is not 'good' or 'bad' on its own. Compare it with the peer average (25.3) and with TECH's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting TECH's P/E ratio (61.85), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Bio-Techne's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.